Agile Therapeutics Shares Outstanding 2013-2018 | AGRX

Agile Therapeutics shares outstanding from 2013 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Agile Therapeutics Annual Shares Outstanding
(Millions of Shares)
2018 34
2017 31
2016 28
2015 22
2014 11
2013 0
2012 0
Agile Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q4 2018 34
Q3 2018 34
Q2 2018 34
Q1 2018 34
Q4 2017 31
Q3 2017 32
Q2 2017 29
Q1 2017 29
Q4 2016 28
Q3 2016 29
Q2 2016 29
Q1 2016 27
Q4 2015 22
Q3 2015 22
Q2 2015 22
Q1 2015 21
Q4 2014 11
Q3 2014 19
Q2 2014 8
Q1 2014 1
Q4 2013 0
Q3 2013 0
Q2 2013 0
Q4 2012 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.070B $0.000B
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.308B 9.06
Teva Pharmaceutical Industries (TEVA) Israel $16.789B 5.79
Mylan (MYL) United Kingdom $14.493B 6.13
Bausch Health Cos (BHC) Canada $8.388B 5.97
Dr Reddy's Laboratories (RDY) India $6.454B 25.74
Supernus Pharmaceuticals (SUPN) United States $1.988B 18.45
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.826B 2.97
Homology Medicines (FIXX) United States $0.994B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.933B 87.96
CymaBay Therapeutics (CBAY) United States $0.764B 0.00
Voyager Therapeutics (VYGR) United States $0.641B 0.00
Assembly Biosciences (ASMB) United States $0.517B 0.00
Akorn (AKRX) United States $0.424B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.374B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.214B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.105B 0.00
Acasti Pharma (ACST) Canada $0.084B 0.00
Teligent (TLGT) United States $0.075B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.023B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00